checkAd

     133  0 Kommentare ProKidney Announces Four Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2023

    Total of 6 abstracts accepted for publication in Kidney Week 2023 program

    WINSTON-SALEM, N.C., Oct. 30, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that the Company will present four posters discussing investigations into the mechanism of action and clinical outcomes observed with REACT (rilparencel) at the upcoming American Society of Nephrology’s (ASN) Kidney Week being held on November 2-5, 2023, in Philadelphia, PA.

    The titles for the accepted abstracts are provided below and accessible online at: https://www.asn-online.org/education/kidneyweek/2023/program-search-ab ....

    ASN Kidney Week attendees are also invited to visit the ProKidney booth (#938) during exhibit hours for additional information on REACT.

    Poster Presentations

    Renal autologous cell therapy (REACT) to delay dialysis in advanced CKD
    Session Title: Diabetic Kidney Disease: Clinical - I
    Session Date & Time: November 2, 2023, from 10:00 AM to 12:00 PM EDT
    Poster Board #: TH-PO169

    Selected Renal Cells Express a Podocyte-Parietal Epithelial Cell Transcriptome
    Session Title: Glomerular Diseases: Podocyte Biology - I
    Session Date, Time: November 2, 2023, from 10:00 AM to 12:00 PM EDT
    Poster Board #: TH-PO739

    Selected Renal Cells Exhibit Renal Tubule Formation Associated with Transforming Growth Factor B2 Expression
    Session Title: Pediatric Nephrology - II
    Session Date, Time: November 3, 2023, from 10:00 AM to 12:00 PM EDT
    Poster Board #: FR-PO637

    Selected Renal Cells Improve Renal Function in a Canine Model of Chronic Kidney Disease
    Session Title: Development, Organoids, Vascularized Kidneys, Nephrons, and More
    Session Date, Time: November 4, 2023, from 10:00 AM to 12:00 PM EDT
    Poster Board #: SA-PO354

    Publication Only

    Osteopontin-Associated Reparative Effects of Selected Renal Cells
    Abstract: PUB085

    Selected Renal Cells Express Cell Adhesion Markers and Form Renal Tubules
    Abstract: PUB086

    Following the event, a copy of the poster presentations will be available on the Company’s website at https://investors.prokidney.com/news-events/events-and-presentations.

    Additional information on ASN Kidney Week 2023 can be accessed online at https://www.asnonline.org/education/kidneyweek/.

    About ProKidney
    ProKidney, a pioneer in the treatment of CKD through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, REACT (Renal Autologous Cell Therapy), is a first-of-its-kind, patented, proprietary autologous cellular therapy being evaluated to potentially preserve kidney function in diabetic patients at high risk of kidney failure. REACT has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting its ongoing Phase 3 clinical program that launched in January 2022. For more information, please visit www.prokidney.com.

    Seite 1 von 3



    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    ProKidney Announces Four Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2023 Total of 6 abstracts accepted for publication in Kidney Week 2023 programWINSTON-SALEM, N.C., Oct. 30, 2023 (GLOBE NEWSWIRE) - ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on …